MDS 2021 | The efficacy of amantadine as an early add-on for motor complications

Caroline Tanner, MD, PhD, FAAN, Weill Institute for Neurosciences, University of California, San Francisco, CA, describes the findings of a subgroup analysis assessing the effectiveness of amantadine delayed-release/extended-release formulation as an early add-on for motor complications of Parkinson’s disease. The subgroup analysis looked at the ability of amantadine to reduce dyskinesia and improve off time in patients early in their disease course and in patients only receiving levodopa monotherapy. Dr Tanner describes that the study showed amantadine to reduce the severity of dyskinesia and improve off time in patients with early disease comparably to the overall study population. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.